Evidence Table H-7: Surgery

Evidence Table H-7a: Surgery Trials\*

| **Author, yearCountryOverall Quality Rating**  | **Eligibility Criteria** | **Exclusion Criteria** | **Number Screened/ Eligible/ Enrolled/ Analyzed** | **AgeSexRace** | **Intervention Type** | **Ulcer Type/Severity at Baseline (Intervention Onset)** | **Proportion Treatment Naïve** | **Treatment A**  | **Treatment B** | **Treatment C** | **Duration of Followup** | **Study Setting** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Juri, 1987135ArgentinaPoor | Nursing home patients admitted to hosp ital, PU stage III and IV | Mentally incapacitating diseases Conditions that could have influenced the results of the study Young patients  | 66/NR/60/60 | Age (Mean): 66.5 yearsFemale: NRRace: NR | Surgery - debridement with closure by tissue flap or skin graft | Stage III or IV | NR | CO2 laser surgery | Conventional surgery | NA | Until hospital discharge - up to 76 days | Hospital |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Evidence Table H-7a: Surgery Trials,\* continued |  |  |  |  |  |  |  |  |
| **Author, yearCountryOverall Quality Rating** | **Outcomes: Complete Wound Healing** | **Outcomes: Wound Surface Area** | **Outcomes: Healing Time** | **Outcomes: Infection Rate** | **Outcomes: Osteomyelitis Rate** | **Outcomes: Recurrence Rate/Flap Failure** | **Outcomes: Pain** | **Other Outcomes: Specify** |
| Juri, 1987135ArgentinaPoor | NR | NR | NR | Treatment A: 11/30 (36.7%)Treatment B: 14/30 (46.7%), p<0.005 | NR | Failure rate:Treatment A: 19% (5)Treatment B: 24% (6) p=NS | NR | Hospital Days: Treatment A: 25 Treatment B: 58p<0.01 |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Evidence Table H-7a: Surgery Trials,\* continued |  |  |  |  |  |  |  |  |
| **Author, yearCountryOverall Quality Rating** | **Harms: Pain**  | **Harms: Dermatologic Complications** | **Harms: Bleeding** | **Harms: Infection** | **Other Harms: Specify** | **Severe Adverse Events** | **Withdrawal due to Adverse Events** | **Overall Adverse Events Rate** |
| Juri, 1987135ArgentinaPoor | NR | NR | Blood Loss: Treatment A: 2.1cm3/cm2 Treatment B: 2.6 cm3/cm2 p<0.01 | NR | NR | Mortality Treatment A: 4/30  (13.3%), Treatment B: 5/30 (16.7%), NS | NR | NR |

\* Observational studies for the Surgical Interventions section of the report were assessed and data was extracted into evidence tables, however, due to the paucity of reported data, we have opted to present only the key details and results of these studies in the in-text summary tables included within the body of the report (Table 12).